Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer

The United States Food and Drug Administration has warned against changing the dosing regimen, interval, or mixing of COVID-19 vaccines in a statement issued Monday. What Happened: The health agency recognized that available data indicates the use of two specified doses of the COVID-19 vaccines — made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) — at specified intervals.

FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments

Its new baseline case forecast for the year is 600 million doses.

Moderna Lifts Its Estimate for 2021 Coronavirus Vaccine Production by 20%

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

The COVID-19 vaccine could be the first of a long list of successes.

The Worst Mistake Moderna Investors Can Make Right Now

A government official suggested that Americans should be given one dose instead of two doses of Moderna Inc.'s COVID-19 vaccine to speed up the number of immunizations in the U.S.

Slaoui proposes a single dose of Moderna's COVID-19 vaccine to speed vaccinations

MRNA stock isn't under the radar any longer, but it is priced below where it ought to be as Covid-19 vaccines will remain in heavy demand. The post Grab Falling Moderna Shares as the Vaccine Rollout Goes Global appeared first on InvestorPlace.

Grab Falling Moderna Shares as the Vaccine Rollout Goes Global

Moderna Inc (NASDAQ: MRNA) shares were advancing Monday after the coronavirus vaccine manufacturer issued an update on its supply goals. What Happened: Cambridge, Massachusetts-based Moderna said it is raising the base-case 2021 global production estimate for its investigational coronavirus vaccine mRNA-1273 from 500 million doses to 600 million doses.

Moderna Raises COVID-19 Vaccine Supply Estimate, Sending Stock Higher

AstraZeneca

Tesla

Tech Finishes as the Strongest Sector in 2020

Moderna is upping the minimum number of doses it expects to make to 600 million, the company said Monday.

Moderna increases minimum 2021 Covid vaccine production by 20% to 600 million doses

Shares of Moderna Inc. gained 0.4% in trading on Monday after the biotechnology company said it plans to produce 100 million doses of its COVID-19 vaccine in the first quarter for the U.S. market. That is the equivalent of 50 million vaccinations as the Moderna vaccine requires two doses.

Moderna expects to deliver 100 million doses of its COVID-19 vaccine in the U.S. in Q1

Moderna Inc on Monday raised the lower end of its 2021 forecast for COVID-19 vaccine production by 100 million doses.

Moderna raises annual vaccine production forecast by 100 million doses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna provides COVID-19 Vaccine supply update.

Moderna Provides COVID-19 Vaccine Supply Update

The biotech's stock fell nearly 32% last month. Piper Sandler analyst Ted Tenthoff argues that investors should give it a second look.

Moderna Stock Is Starting the Year With a Bump

While vaccine stocks slipped on a “sell-the-news” reaction, there's still plenty of opportunity to be found, including MRNA stock. The post Use Weakness in Moderna as Buying Opportunity appeared first on InvestorPlace.

Use Weakness in Moderna as Buying Opportunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to provide business and pipeline updates at the 2021 J.P. Morgan Healthcare Conference.

Moderna to Provide Business and Pipeline Updates at the 2021 J.P. Morgan Healthcare Conference

Operation Warp Speed Chief Adviser Moncef Slaoui said Sunday that Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine could be administered at half the regular volume to some people in order to bolster availability. What Happened: The chief of the government's COVID-19 vaccine project told CBS News' “Face The Nation” program that giving two doses of Moderna vaccine, at half the regular volume each, to people aged between 18 and 55 could achieve the objective of “immunizing double the number of people”  with the existing number of doses.

US Considers Ramping Up COVID-19 Vaccine Supply By Halving Moderna Doses For Some People

Investors in the COVID-19 vaccine maker took some profits last month.

Why Moderna Stock Fell 32% in December

Moncef Slaoui told CBS that Operation Warp Speed is looking at giving half doses of the Moderna vaccine to certain groups to speed up the Covid vaccine rollout.

U.S. could ramp up slow Covid vaccine rollout by giving two half volume doses of Moderna shot, Slaoui says

Apple

SPDR Gold Trust

Cummins

Apple, the gold ETF, Moderna and Cummins were our top stock trades as head into the first trading session of 2021. Let's look at the charts.

4 Top Stock Trades for Monday: AAPL, GLD, MRNA, CMI

Moderna's Covid-19 vaccine has finally made its way across the country. MRNA stock continues to lose altitude.

Moderna's Share Price Continues to Lose Altitude

With the recent drop in MRNA stock, there looks like a nice opportunity for long-term investors. The post Moderna Stock Is More Than The Covid-19 Vaccine appeared first on InvestorPlace.

Moderna Stock Is More Than The Covid-19 Vaccine

Moderna reaps the rewards of its Covid-19 vaccine, and MRNA stock is worth 57% to 172% more based on near-term and long-term earnings power. The post Moderna Stock Is Worth Much More appeared first on InvestorPlace.

Moderna Stock Is Worth Much More

Moderna Inc. on Friday confirmed that it has agreed to supply the South Korean government with 40 million doses of its COVID-19 vaccine. Deliveries are expected to start in May of 2021.

Moderna to provide Korea with 40 million doses of its COVID vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces publication of results from the pivotal Phase 3 trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine.

Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna confirms 40 million COVID-19 vaccine dose supply agreement with the Government of the Republic of Korea.

News for Moderna Stock (MRNA)